NEJM 'Under Review': What Each Status Means and When to Expect a Decision

NEJM is one of the fastest top-tier journals. The median time to first decision is about 21 days, even for papers that go through full peer review. This speed is intentional: NEJM knows that practice-changing clinical data needs to reach physicians quickly.

NEJM's desk rejection rate is the highest among general medical journals. Editors are looking for one thing above all else: will this change medical practice?

Papers that survive the desk have usually demonstrated:

• A large, well-designed clinical trial with a definitive answer to a treatment question
• Findings that would immediately change clinical guidelines
• Adequate statistical power for the claims being made
• Clear clinical significance, not just statistical significance
• Relevance to a broad physician audience, not just subspecialists

If you've made it past the desk, the editor believes your paper has genuine potential to change how medicine is practiced. That's a strong signal about your work's quality and significance.

NEJM typically assigns 2-3 reviewers. The selection is targeted:

• At least one reviewer with direct clinical expertise in your area
• Often a biostatistician or methodologist for trial data
• Sometimes a reviewer from outside your exact specialty to assess broader relevance

What reviewers evaluate:

• Is the clinical trial design sound? Were biases adequately controlled?
• Are the endpoints clinically meaningful (not just surrogate markers)?
• Is the treatment effect large enough to change practice?
• Are the safety data adequate? Any concerning adverse events?
• Could these findings be replicated and generalized to other populations?
• Is the paper written clearly enough for NEJM's broad readership?

NEJM reviews tend to be shorter and more focused than reviews at basic science journals. Reviewers know the editors have already vetted the science for significance. The review focuses on validity and clinical impact rather than novelty or completeness.

NEJM's speed advantage is real. Where other journals take 6-12 weeks for a first decision, NEJM targets 3 weeks. For urgent clinical findings (safety signals, pandemic data, breakthrough therapies), the process can be even faster.

Accept without revision. Rare. Maybe 5% of papers that reach review get a clean accept. If you receive one, it means the reviewers and editors see no significant concerns.

Accept with minor revision. More common. Small clarifications, additional subgroup analyses, or editorial adjustments to the text. Turnaround is usually 2-4 weeks.

Major revision. The most common positive outcome. Significant additional analyses, better explanation of methodology, or addressing specific reviewer concerns. NEJM revision requests are specific and achievable. They don't typically ask for additional clinical trials or major new data collection.

Reject after review. This happens. Even clearing the desk doesn't guarantee publication. Perhaps 40-50% of reviewed papers are ultimately rejected. The editor's letter will explain what fell short.

If you get a revision invitation:

1. Respond to every reviewer point. Point-by-point response is essential. Don't skip or dismiss any concern.
2. Be concise. NEJM values brevity. Don't pad your response with unnecessary detail.
3. Do the additional analyses if asked. If a reviewer wants a subgroup analysis or sensitivity analysis, do it. These requests are usually reasonable.
4. Don't add unrequested data. Stick to what's asked. Adding new findings complicates re-review.
5. Respect the timeline. NEJM gives revision deadlines. Meet them. If you need an extension, ask early.
6. Track changes. Provide a version with changes highlighted and a clean version. Make it easy for reviewers and editors.

• 0-2 weeks under review: Don't contact the journal. This is normal.

• 3 weeks: Still within expected range. Wait.

• 4 weeks: Approaching the upper end. A brief, polite inquiry to the editorial office is reasonable.

• 5+ weeks: Follow up if you haven't heard back. Something unusual may have happened (reviewer delays, editorial transition).

Keep inquiries short: "I'm writing to check on the status of manuscript NEJM-XXXX. Any update on expected timeline would be appreciated."

• NEJM journal guide
• JAMA vs NEJM - head-to-head comparison
• Lancet under review - comparing the Lancet process
• Acceptance rates across 50+ journals
• Review timelines compared

In our pre-submission review work with manuscripts targeting NEJM, three failure patterns generate the most consistent desk rejections. We find these across manuscripts we've reviewed through our NEJM submission readiness check.

The trial that reports surrogate endpoints without clinical outcome data. NEJM's editorial threshold is outcomes that matter to patients: mortality, morbidity, hospitalization, or quality of life. We observe that trials powered for a surrogate endpoint (such as a biomarker change or imaging finding) and reporting that as the primary result generate desk rejections citing insufficient clinical significance in roughly half of cases we review. NEJM editors explicitly ask whether the finding changes what a clinician does at the bedside, and biomarker changes without a clinical outcome link do not clear this bar. Trials that include a clinical outcome as at least a key secondary endpoint clear the desk at substantially higher rates.

The large observational study with unresolved confounding. NEJM publishes observational research, but the bar for confounding control is high. We observe that population-based studies claiming a causal relationship between an exposure and an outcome without pre-specified sensitivity analyses for the major potential confounders generate reviewer requests for additional analyses in the majority of cases. SciRev community data for NEJM identifies "insufficient confounding adjustment" and "causal language in observational design" as recurring revision themes. Pre-registering the sensitivity analyses and labeling the association as associative rather than causal in the abstract prevents this predictable request.

The RCT abstract that does not state clearly whether the primary endpoint was met. NEJM reviewers evaluate whether the abstract gives a complete and honest account of the trial result. We observe that abstracts leading with a positive secondary outcome when the primary endpoint did not reach statistical significance generate requests for abstract revision in nearly every case. The NEJM abstract must state clearly and upfront whether the pre-specified primary endpoint was met.